TITLE

CLINIC ROUNDUP

PUB. DATE
October 2009
SOURCE
BioWorld Today;10/15/2009, Vol. 20 Issue 199, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs related to biotechnology. Intercell AG of Vienna, Austria, entered phase III development for their travelers' diarrhea vaccine patch. ZyStor Therapeutics Inc. received clearance from the U.S. Food and Drug Administration for a phase I study of its enzyme replacement therapy ZC-701. Data from the Phase II trial of Rexin-G from Epeius Biotechnologies Inc. showed improved tumor responses.
ACCESSION #
44683546

 

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics